iData Insights

Malignant Mesothelioma - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 23, 2016 14:33 IST

Malignant Mesothelioma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Malignant Mesothelioma - Pipeline Review, H2 2015 , provides an overview of the Malignant Mesothelioma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173361/malignant-mesothelioma-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173361/malignant-mesothelioma-pipeline-review-h2-2015

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Malignant Mesothelioma Overview 10

Therapeutics Development 11

Pipeline Products for Malignant Mesothelioma - Overview 11

Pipeline Products for Malignant Mesothelioma - Comparative Analysis 12

Malignant Mesothelioma - Therapeutics under Development by Companies 13

Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes 18

Malignant Mesothelioma - Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Malignant Mesothelioma - Products under Development by Companies 22

Malignant Mesothelioma - Products under Investigation by Universities/Institutes 26

Malignant Mesothelioma - Companies Involved in Therapeutics Development 27

Aduro BioTech, Inc. 27

Advantagene, Inc. 28

Aeolus Pharmaceuticals, Inc. 29

Amphera BV 30

AnGes MG, Inc. 31

arGEN-X BV 32

ArQule, Inc. 33

AVEO Pharmaceuticals, Inc. 34

Bayer AG 35

Berg LLC 36

Biogen, Inc. 37

Bionomics Limited 38

Biotecnol, Inc. 39

Boehringer Ingelheim GmbH 40

Boston Biomedical, Inc. 41

Bristol-Myers Squibb Company 42

Calithera Biosciences, Inc. 43

CanBas Co., Ltd. 44

Concordia Healthcare Corp. 45

CritiTech, Inc. 46

Deciphera Pharmaceuticals, LLC 47

Eagle Pharmaceuticals, Inc. 48

Eisai Co., Ltd. 49

Eli Lilly and Company 50

EnGeneIC Ltd 51

F. Hoffmann-La Roche Ltd. 52

Five Prime Therapeutics, Inc. 53

Genelux Corporation 54

GlaxoSmithKline Plc 55

Juno Therapeutics Inc. 56

Karyopharm Therapeutics, Inc. 57

Kyowa Hakko Kirin Co., Ltd. 58

MedImmune, LLC 59

Merck & Co., Inc. 60

Merck KGaA 61

Millennium Pharmaceuticals, Inc. 62

MolMed S.p.A. 63

Morphotek, Inc. 64

Novartis AG 65

Ono Pharmaceutical Co., Ltd. 66

Oxford BioMedica Plc 67

Pfizer Inc. 68

Pharma Mar, S.A. 69

Polaris Pharmaceuticals, Inc. 70

Progenra, Inc. 71

Sellas Inc. 72

Sorrento Therapeutics, Inc. 73

Synta Pharmaceuticals Corp. 74

Targovax AS 75

TRACON Pharmaceuticals, Inc. 76

VasGene Therapeutics, Inc. 77

Verastem, Inc. 78

Virttu Biologics Limited 79

Y's Therapeutics Co., Ltd. 80

Malignant Mesothelioma - Therapeutics Assessment 81

Assessment by Monotherapy Products 81

Assessment by Combination Products 82

Assessment by Target 83

Assessment by Mechanism of Action 86

Assessment by Route of Administration 89

Assessment by Molecule Type 91

Drug Profiles 93

Ad5-SGE-REIC/Dkk3 - Drug Profile 93

AEOL-10150 - Drug Profile 95

alisertib - Drug Profile 98

amatuximab - Drug Profile 102

anetumab ravtansine - Drug Profile 105

ARGX-110 - Drug Profile 107

ascrinvacumab - Drug Profile 110

AV-203 - Drug Profile 111

avelumab - Drug Profile 112

bevacizumab - Drug Profile 114

BG-00001 - Drug Profile 120

BIW-8962 - Drug Profile 121

BMS-986148 - Drug Profile 122

BNC-105 - Drug Profile 123

CB-839 - Drug Profile 125

CBP-501 - Drug Profile 127

Cellular Immunotherapy 2 for Oncology - Drug Profile 129

Cellular Immunotherapy for Cancer - Drug Profile 130

Cellular Immunotherapy for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 131

Cellular Immunotherapy to Target CSPG4 for Oncology - Drug Profile 132

CRS-207 - Drug Profile 133

Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 136

DP-3975 - Drug Profile 137

DPV-001 - Drug Profile 138

E-7449 - Drug Profile 140

FL-118 - Drug Profile 141

FP-1039 - Drug Profile 144

ganetespib - Drug Profile 146

GEN-0101 - Drug Profile 151

Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 153

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 154

GLONC-1 - Drug Profile 155

GSK-2256098 - Drug Profile 158

HSV-1716 - Drug Profile 160

iCasp9M28z - Drug Profile 163

JTCR-016 - Drug Profile 164

KPT-251 - Drug Profile 165

LY-3023414 - Drug Profile 166

MesoCancerVac - Drug Profile 168

MesoCART - Drug Profile 169

Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile 170

MV-NIS - Drug Profile 172

napabucasin - Drug Profile 174

NGR-hTNF - Drug Profile 177

nintedanib - Drug Profile 181

nivolumab - Drug Profile 186

ONCOS-102 - Drug Profile 194

Oshadi D + Oshadi R - Drug Profile 196

OXB-301 - Drug Profile 197

P-0005091 - Drug Profile 200

paclitaxel - Drug Profile 201

pegargiminase - Drug Profile 202

pembrolizumab - Drug Profile 206

pemetrexed disodium - Drug Profile 215

porfimer sodium - Drug Profile 216

rAd-IFN - Drug Profile 218

Small Molecules to Inhibit Bcl-2 Survival Proteins for Cancer - Drug Profile 220

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 221

TargomiRs - Drug Profile 222

Tb-535 - Drug Profile 224

tivantinib - Drug Profile 225

trabectedin - Drug Profile 227

TRC-102 - Drug Profile 232

tremelimumab - Drug Profile 234

ubidecarenone - Drug Profile 237

Vaccine for Cancer - Drug Profile 239

Vaccine to Target WT1 for Cancer - Drug Profile 240

Vas-01 - Drug Profile 241

VS-4718 - Drug Profile 243

VS-5584 - Drug Profile 244

YS-110 - Drug Profile 246

Malignant Mesothelioma - Recent Pipeline Updates 247

Malignant Mesothelioma - Dormant Projects 354

Malignant Mesothelioma - Discontinued Products 356

Malignant Mesothelioma - Product Development Milestones 357

Featured News & Press Releases 357

Appendix 366

Methodology 366

Coverage 366

Secondary Research 366

Primary Research 366

Expert Panel Validation 366

Contact Us 366

Disclaimer 367

Read More http://www.idatainsights.com/reports-landing-page.php?id=173361/malignant-mesothelioma-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects